Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells XLA diagnosis or not?

Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells : XLA diagnosis or not?

The identification of a Btk mutation in a male patient with <2% CD19(+) B cells warrants making the diagnosis of X-linked Agammaglobulinemia (XLA). Herein we report the case of a 31 year-old male with a gradual decline of peripheral B lymphocytes and low IgA and IgM but normal IgG levels. His cli...

Description complète

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 128(2008), 3 vom: 16. Sept., Seite 322-8
Auteur principal: Graziani, Simona (Auteur)
Autres auteurs: Di Matteo, Gigliola, Benini, Luigi, Di Cesare, Silvia, Chiriaco, Maria, Chini, Loredana, Chianca, Marco, De Iorio, Fosca, La Rocca, Maria, Iannini, Roberta, Corrente, Stefania, Rossi, Paolo, Moschese, Viviana
Format: Article en ligne
Langue:English
Publié: 2008
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Case Reports Journal Article Research Support, Non-U.S. Gov't Protein-Tyrosine Kinases EC 2.7.10.1 Agammaglobulinaemia Tyrosine Kinase EC 2.7.10.2 BTK protein, human
Description
Résumé:The identification of a Btk mutation in a male patient with <2% CD19(+) B cells warrants making the diagnosis of X-linked Agammaglobulinemia (XLA). Herein we report the case of a 31 year-old male with a gradual decline of peripheral B lymphocytes and low IgA and IgM but normal IgG levels. His clinical history revealed recurrent respiratory and skin infections, sclerosing cholangitis and chronic obstructive pancreatitis. Molecular studies revealed a novel aminoacidic substitution in Btk protein (T316A). His mother, maternal aunts and a maternal female cousin were heterozygotes for the same Btk mutation and were variably affected with pulmonary emphysema. This is a puzzling case where the patient's clinical history and laboratory findings divorce molecular genetics. Either this case confirms the variable expressivity of XLA disease or the T316A change in Btk SH2 domain is a novel non-pathogenic mutation and another unknown gene alteration is responsible for the disease
Description:Date Completed 05.09.2008
Date Revised 01.12.2018
published: Print
CommentIn: Clin Immunol. 2008 Sep;128(3):285-6. doi: 10.1016/j.clim.2008.04.013. - PMID 18617443
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2008.05.012